Medical Director - Early Development - Cardio-metabolic
Amgen is a leading global biotechnology company, with a mission to serve patients around the world. As a Science based, patient focused organization, we discover and develop innovative therapies to treat serious illnesses. Our medicines have made a dramatic difference in the lives of millions. To underpin our commitment to serve patients, Amgen continues to develop our translational medicine focus in the cardio-metabolic therapeutic area in support of preclinical and clinical programs.
Medical Sciences is looking for a strong scientific leader in the cardio-metabolic therapeutic area. This individual will be responsible for providing scientific/ medical direction and leadership for pre-clinical/ early clinical programs for Amgen's early development cardio-metabolic pipeline. The Medical Director will lead the early phase clinical development of compounds in the cardio-metabolic therapeutic area from first-in-man studies through proof of concept and translational projects as part of the initial drug development strategy. This individual will also serve as the project leader for one or more of Amgen's Product Teams through their role as an Early Development Leader (EDL).
This Medical Director will be responsible for representing Medical Sciences during interactions with other Amgen functions and key external stakeholders including regulatory agencies and the scientific community. In addition, they will be responsible for enhancing Amgen's scientific capabilities in the area cardio-metabolic therapeutic area.
The role will include the following responsibilities:
Serve as an internal clinical expert for translational and clinical programs in the cardio-metabolic therapeutic area.
Serve as medical monitor for clinical trials and assists in resolving major issues that may affect the studies.
Present information internally and externally, anticipating and proactively managing problems across a broad spectrum of cross-functional teams.
Provide guidance and assistance in the identification and management of phase 1 collaborators, consultants, and/or Clinical Research Organizations (CROs) in completion of key projects.
Ensure appropriate training, recruitment, and development requirements for matrix team resources.
Will be the primary Medical Sciences contact for basic scientists in discovery research as well as for clinical research scientists overseeing later clinical development.
Evaluate external opportunities for partnering or licensing new cardiometabolic assets.
This position can be located in either Thousand Oaks, CA, or San Francisco, CA.
2 years of clinical research and/or basic science research experience
Subspecialty board eligibility/certification in Internal Medicine or Cardiology or Endocrinology
Strong basic science or clinical research background in academia or industry
Prior experience authoring, monitoring, analyzing, and presenting clinical trial data
Excellent interpersonal, verbal and written communication skills and the experience of successfully functioning in a highly matrixed team environment
Ability to anticipate problems and find creative solutions
In-depth understanding of the scientific method and clinical applications based on medical, scientific and practical rationale including working knowledge of biomarker methods and clinical imaging endpoints
A record of high quality peer-reviewed publications
An understanding of regulatory requirements necessary for the various phases of drug development and experience interacting with regulators
Demonstrated ability of flexibility, efficiency and diplomacy both individually and as part of a team effort
Previous experience in early phase development and/or biomarker work
Previous experience in late stage clinical trials and regulatory filings
Demonstrated expertise in conducting translational and/or clinical research.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.